Scarica l'app Stockscreener
7.925
2.59%
0.195
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GRFS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Grifols Sa Adr Borsa (GRFS) Ultime notizie
Grifols S.A. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SMRT’s latest rating updates from top analysts. - knoxdaily.com
Investing in Grifols SA ADR (GRFS): What You Must Know - knoxdaily.com
Investing in Apellis Pharmaceuticals Inc (APLS) Is Getting More Attractive - knoxdaily.com
A company insider recently sold 10,000 shares of News Corp [NWSA]. Should You also Consider to Sale? - knoxdaily.com
Raymond James Downgrades Truist Financial Corporation (TFC) to a Mkt perform from an Outperform - knoxdaily.com
AT&T, Inc (T) rating upgrades by Exane BNP Paribas - knoxdaily.com
Grifols SA ADR (GRFS) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Lazard Inc (LAZ) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Can Verra Mobility Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
RYAN’s Market Whiplash: 0.32% YTD Rise, -10.03% Plunge in 30 Days - investchronicle.com
A significant driver of top-line growth: Grifols SA ADR (GRFS) - Sete News
SpringWorks Therapeutics Inc (SWTX) Stock: From Low to High in 52 Weeks - investchronicle.com
There is no doubt that Coeur Mining Inc (CDE) ticks all the boxes. - Sete News
GRFS (Grifols SA ADR) may reap gains as insiders became active recently - knoxdaily.com
BHP’s latest rating updates from top analysts. - knoxdaily.com
FHN’s latest rating updates from top analysts. - knoxdaily.com
Lake Street’s latest rating for ORGO stock - knoxdaily.com
Fox Corporation [FOX] stock was sold by MURDOCH KEITH RUPERT at the price of US$3.08 million - knoxdaily.com
6 undervalued stocks with low beta - Morningstar
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Barchart
BRF S.A. goes ex dividend tomorrow - MSN
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - MSN
Grifols falls amid potential Moody's downgrade, new short report - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Orange To Delist From NYSE To Reduce Financial Burdens - Yahoo Finance
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols, S.A. (BME:GRF) most popular amongst retail investors who own 45% of the shares, institutions hold 35% - Simply Wall St
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A.GRFS - PR Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
Grifols sees China stake sale going ahead despite Gotham City report - Reuters
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients - PR Newswire UK
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Novo Nordisk A/s Dividend History & Dividend Yield 2024 - INDmoney
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire
8 Newly Undervalued 5-Star Stocks - Morningstar
Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022 - PR Newswire
OZTA Stock Price and Chart — BER:OZTA - TradingView
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies - PR Newswire
How International Is Your Foreign-Stock Fund? - Morningstar
Estimating The Fair Value Of Grifols SA. (BME:GRF) - Yahoo Finance
GRF Stock Price and Chart — BME:GRF - TradingView
7.13%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):